These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

279 related articles for article (PubMed ID: 37108147)

  • 1. Cardiovascular Complications in Patients with Prostate Cancer: Potential Molecular Connections.
    Kakkat S; Pramanik P; Singh S; Singh AP; Sarkar C; Chakroborty D
    Int J Mol Sci; 2023 Apr; 24(8):. PubMed ID: 37108147
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Androgen deprivation therapy and cardiovascular disease.
    Melloni C; Roe MT
    Urol Oncol; 2020 Feb; 38(2):45-52. PubMed ID: 30879969
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cardiovascular disease risk assessment and multidisciplinary care in prostate cancer treatment with ADT: recommendations from the APMA PCCV expert network.
    Merseburger AS; Bakshi G; Chen DY; Chiong E; Jabbour M; Joung JY; Lai AY; Lawrentschuk N; Le TA; Ng CF; Ng CT; Ong TA; Pang JS; Rabah DM; Ragavan N; Sase K; Suzuki H; Teo MMH; Uemura H; Woo HH
    World J Urol; 2024 Mar; 42(1):156. PubMed ID: 38483562
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Is androgen deprivation therapy for prostate cancer associated with cardiovascular disease? A meta-analysis and systematic review.
    Liang Z; Zhu J; Chen L; Xu Y; Yang Y; Hu R; Zhang W; Song Y; Lu Y; Ou N; Liu X
    Andrology; 2020 May; 8(3):559-574. PubMed ID: 31743594
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Perspectives on the Cardiovascular and Metabolic Effects of Androgen Deprivation Therapy in Prostate Cancer.
    Sentana-Lledo D; Morgans AK
    Curr Oncol Rep; 2024 Mar; 26(3):299-306. PubMed ID: 38376624
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Approaches to Prevent and Manage Cardiovascular Disease in Patients Receiving Therapy for Prostate Cancer.
    Ng CT; Bonilla HMG; Bryce AH; Singh P; Herrmann J
    Curr Cardiol Rep; 2023 Aug; 25(8):889-899. PubMed ID: 37490155
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cardiometabolic side effects of androgen deprivation therapy in prostate cancer.
    Lafontaine ML; Kokorovic A
    Curr Opin Support Palliat Care; 2022 Dec; 16(4):216-222. PubMed ID: 36349380
    [TBL] [Abstract][Full Text] [Related]  

  • 8. EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer.
    Heidenreich A; Bastian PJ; Bellmunt J; Bolla M; Joniau S; van der Kwast T; Mason M; Matveev V; Wiegel T; Zattoni F; Mottet N;
    Eur Urol; 2014 Feb; 65(2):467-79. PubMed ID: 24321502
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Quantifying observational evidence for risk of fatal and nonfatal cardiovascular disease following androgen deprivation therapy for prostate cancer: a meta-analysis.
    Bosco C; Bosnyak Z; Malmberg A; Adolfsson J; Keating NL; Van Hemelrijck M
    Eur Urol; 2015 Sep; 68(3):386-96. PubMed ID: 25484142
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Androgen deprivation therapy in prostate cancer and metabolic risk for atherosclerosis.
    Shahani S; Braga-Basaria M; Basaria S
    J Clin Endocrinol Metab; 2008 Jun; 93(6):2042-9. PubMed ID: 18349064
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Update on cardiovascular and metabolic risk profiles of hormonal agents used in managing advanced prostate cancer.
    Higano CS
    Urol Oncol; 2020 Dec; 38(12):912-917. PubMed ID: 32900627
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Emerging cardiometabolic complications of androgen deprivation therapy.
    Choong K; Basaria S
    Aging Male; 2010 Mar; 13(1):1-9. PubMed ID: 20148744
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cardiovascular risk with androgen deprivation therapy for prostate cancer: potential mechanisms.
    Tivesten Å; Pinthus JH; Clarke N; Duivenvoorden W; Nilsson J
    Urol Oncol; 2015 Nov; 33(11):464-75. PubMed ID: 26141678
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Approach to Androgen Deprivation in the Prostate Cancer Patient with Pre-existing Cardiovascular Disease.
    Greiman AK; Keane TE
    Curr Urol Rep; 2017 Jun; 18(6):41. PubMed ID: 28417429
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The role of exercise in the management of adverse effects of androgen deprivation therapy for prostate cancer: a rapid review.
    Edmunds K; Tuffaha H; Scuffham P; Galvão DA; Newton RU
    Support Care Cancer; 2020 Dec; 28(12):5661-5671. PubMed ID: 32699997
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term effects of androgen deprivation therapy in prostate cancer patients.
    Basaria S; Lieb J; Tang AM; DeWeese T; Carducci M; Eisenberger M; Dobs AS
    Clin Endocrinol (Oxf); 2002 Jun; 56(6):779-86. PubMed ID: 12072048
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CaV1.3 enhanced store operated calcium promotes resistance to androgen deprivation in prostate cancer.
    O'Reilly D; Downing T; Kouba S; Potier-Cartereau M; McKenna DJ; Vandier C; Buchanan PJ
    Cell Calcium; 2022 May; 103():102554. PubMed ID: 35193095
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cardiovascular Effects of Androgen Deprivation Therapy in Prostate Cancer.
    Agarwal M; Canan T; Glover G; Thareja N; Akhondi A; Rosenberg J
    Curr Oncol Rep; 2019 Aug; 21(10):91. PubMed ID: 31446509
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cardiovascular risks of androgen deprivation therapy.
    Ribeiro AF; Camara C; Segre CA; Srougi M; Serrano CV
    Arq Bras Cardiol; 2010 Sep; 95(3):412-5. PubMed ID: 20944900
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Metabolic and cardiovascular effects of androgen deprivation therapy.
    Hakimian P; Blute M; Kashanian J; Chan S; Silver D; Shabsigh R
    BJU Int; 2008 Dec; 102(11):1509-14. PubMed ID: 18727614
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.